Sun Pharma Appoints Former PwC India COO Satyavati Berera as Independent Director
Sun Pharmaceutical Industries has appointed Ms. Satyavati Berera, former Chief Operating Officer of PwC India, as an Independent Director for a five-year term subject to shareholder approval. Ms. Berera brings over 40 years of leadership experience and extensive expertise in Assurance, Consulting, and Governance Risk and Compliance services, strengthening the company's board governance structure.
*this image is generated using AI for illustrative purposes only.
Sun Pharmaceutical Industries has announced the appointment of Ms. Satyavati Berera as an independent director to its board of directors. The appointment, approved by the company's board based on the recommendation of the Nomination and Remuneration Committee, is for a term of five years and is subject to shareholder approval.
Board Appointment Details
The pharmaceutical company's board has made this strategic appointment to strengthen its governance structure. The key details of the appointment are outlined below:
| Parameter: | Details |
|---|---|
| Appointee: | Ms. Satyavati Berera |
| DIN: | 05002709 |
| Position: | Independent Director |
| Term Duration: | Five Consecutive Years |
| Status: | Pending Shareholder Approval |
| Effective Date: | From Date of Shareholder Approval |
Professional Background
Ms. Satyavati Berera brings extensive leadership experience to Sun Pharmaceutical Industries' board. Her professional credentials include:
| Qualification: | Details |
|---|---|
| Former Role: | Chief Operating Officer (COO) of PwC India |
| Experience: | 40+ Years in Leadership Roles |
| Retirement: | 2023 from PwC India |
| Education: | Economics Graduate from Lady Shri Ram College, Delhi University |
| Professional Qualification: | Fellow Member of Institute of Chartered Accountants of India (ICAI) |
| CA Qualification Year: | 1984 |
| Partnership: | Partner at Price Waterhouse since 1995 |
Ms. Berera's career progression at PwC included serving as an Audit Partner from 1995 to 2005, heading the consulting practice, and serving as Managing Partner for the firm's northern region before becoming COO in 2016. Her expertise spans across Assurance, Consulting, and Governance Risk and Compliance services (GRC).
Governance and Compliance
The appointment ensures that Sun Pharmaceutical Industries' board composition remains in full compliance with the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ms. Berera is not related to any Director, Key Managerial Personnel, or promoter of the company and is not debarred from holding the office of Director by SEBI or any other authority.
Next Steps
The appointment will require formal ratification by the company's shareholders through postal ballot. Until such approval is obtained, the appointment remains subject to shareholder consent. The company has filed the necessary disclosures under Regulation 30 of SEBI regulations, demonstrating its commitment to transparent governance practices.
Historical Stock Returns for Sun Pharmaceutical
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.02% | -5.67% | -2.50% | +3.51% | -0.28% | +177.30% |
How might Ms. Berera's extensive consulting and governance expertise influence Sun Pharma's strategic direction and operational efficiency?
Will this board strengthening signal potential major corporate initiatives or restructuring plans at Sun Pharmaceutical Industries?
Could the addition of a former Big Four executive indicate Sun Pharma's preparation for enhanced regulatory scrutiny or international expansion?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
